Pasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary

Pasithea Therapeutics

14/08/2026 22:14

Pasithea Therapeutics Corp KTTA.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended June 30.  The lone analyst forecast for the quarter was for a loss of 16 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Pasithea Therapeutics Corp's reported EPS for the quarter was a loss of 16 cents​.
The company reported a quarterly loss of $5.27 million.
Pasithea Therapeutics Corp shares had fallen by 7.3% this quarter and lost 62.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 64.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Pasithea Therapeutics Corp is $3.00, about 84.1% above its last closing price of $0.48
This summary was machine generated from LSEG data August 14 at 09:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.16
-0.16
Met
Mar. 31 2026 
-0.45
-0.12
Beat
Dec. 31 2025 
-0.18
-0.79
Missed